Skip to main content
. 2022 Oct 4;11(19):5866. doi: 10.3390/jcm11195866

Figure 2.

Figure 2

Effects of CCM therapy on NT-proBNP plasma levels (panel (A)), NYHA class (panel (B)), and MLHFQ score (panel (C)). NT-proBNP: N terminal-pro brain natriuretic peptide; NYHA: New York Heart Association; MLHFQ: Minnesota Living with Heart Failure Questionnaire.